Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 14, 2007

View Archived Issues

Positive preclinical results with a combined hepatitis A and E vaccine

Active end to 2006 for Gilead Sciences

T-2000 improves essential tremor in two small studies

Safety and efficacy of a transdermal Alzheimer's Abeta/CT vaccine shown in mice

Promising preclinical results with Domantis domain antibodies against vaginal candidiasis

Lonafarnib to enter clinic for the treatment of progeria syndromes

SIR-Spheres, bevacizumab + chemotherapy studied for metastatic colorectal cancer

Wyeth welcomes decision to fund pneumococcal vaccine for developing countries

Recent patents cover therapeutic agents for cardiovascular disorders

Novel treatment options for HCV infection reported in recent patents

Recent Bayer and AiCuris patents disclose new antiinfective agents

GSK commends pneumococcal vaccine advance market commitment

PEP-005 Topical studied in phase II trial for superficial BCC

Cytyc to acquire Adeza

Micromet exercises option for Morphotek antibody

Ariad grants commercial license to Argent technology to CellNexus

Ambrx studies next-generation human growth hormone product in phase I/II study

Adolor studies novel delta opioid receptor agonists

Avant and Select Vaccines to develop improved viral vaccines

Fast track designation for BioThrax for anthrax post-exposure prophylaxis

Biovail to use Depomed's AcuForm technology

Findings made available from Diabetes Genetics Initiative

Revisions to U.S. prescribing information for Ketek

Interim data support improvements in inflammatory arthritis with tgAAC94

Ono updates recent developments

Accelerated reviews for maraviroc

Recent Pfizer patent discloses novel therapeutic agents for gastrointestinal disorders

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...